affective disorders – mycolab.ai

The therapeutic potential of microdosing psychedelics in depression

mycolabadmin

This review examines whether taking very small doses of psychedelic drugs like LSD and psilocybin might help treat depression. While users report benefits and some studies show subtle positive effects on mood and thinking, scientists have not yet confirmed whether microdosing actually works as a depression treatment. More research with depressed patients is needed to understand if this approach is truly helpful and safe for regular use.

Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience

mycolabadmin

Researchers studied how DMT affects the brain’s ability to switch between different activity patterns. Using simultaneous brain imaging (fMRI) and electrical recordings (EEG), they found that DMT makes these transitions easier and less energy-intensive. The effects occurred primarily in brain regions with high levels of serotonin 2a receptors and were accompanied by increased complexity of brain signals and stronger subjective drug effects.

Erythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus

mycolabadmin

Researchers studied how a protein called erythropoietin (EPO) affects brain cells called interneurons in the hippocampus, a region important for memory and learning. They found that EPO treatment reduces the inhibitory activity of certain interneurons, which makes the brain’s excitatory neurons more active. This change in brain balance could potentially help treat psychiatric disorders like schizophrenia and autism that involve imbalanced brain activity.

Disease: affective disorders

The therapeutic potential of microdosing psychedelics in depression

Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience

Erythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus